Skip to main content
HOUSE 568118th CongressReferred to the House Committee on the Judiciary.

Original LGBTQIA+ Pride Month Resolution of 2023

Last Action
6/30/2023

Actions

  • 2023-02-03Referred to the Subcommittee on Health.
  • 2023-02-01Sponsor introductory remarks on measure. (CR H588)
  • 2023-01-26Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2023-01-26Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2023-01-26Introduced in House
  • 2023-01-26Introduced in House

CRS Summary

As of 2023-01-26 (00)

Save Americans from the Fentanyl Emergency Act or the SAFE Act

This bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. The temporary scheduling order issued by the Drug Enforcement Administration to place fentanyl-related substances into schedule I of the Controlled Substances Act expires on December 31, 2024.

It limits the application of mandatory minimum penalties for certain offenses involving fentanyl-related substances, establishes a process to deschedule or remove certain fentanyl-related substances that have a low potential for abuse, and allows a federal court to vacate or reduce the sentence for convictions of offenses involving a fentanyl-related substance that is descheduled or moved to a schedule other than schedule I or II.

The bill establishes a new, alternative registration process for schedule I research. It also makes other changes to registration requirements for conducting research with controlled substances, including

  • permitting a single registration for related research sites in certain circumstances,
  • waiving the requirement for a new inspection in certain situations, and
  • allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

Finally, the bill requires the Government Accountability Office to analyze the implementation and impact of permanently placing fentanyl-related substances into schedule I of the Controlled Substances Act.

Cosponsors (19)

  • Dan Newhouse (R-WA)
  • Tony Gonzales (R-TX)
  • Maria Salazar (R-FL)
  • Angie Craig (D-MN)
  • Sharice Davids (D-KS)
  • Marie Perez (D-WA)
  • Abigail Spanberger (D-VA)
  • Daniel Kildee (D-MI)
  • Josh Harder (D-CA)
  • Ami Bera (D-CA)
  • Mike Levin (D-CA)
  • Nikki Budzinski (D-IL)
  • Derek Kilmer (D-WA)
  • BETTY MCCOLLUM (D-MN)
  • Jason Crow (D-CO)
  • Donald Davis (D-NC)
  • Jennifer McClellan (D-VA)
  • Seth Magaziner (D-RI)
  • Michael Lawler (R-NY)

Subjects

  • Administrative law and regulatory procedures
  • Congressional oversight
  • Criminal procedure and sentencing
  • Department of Justice
  • Drug trafficking and controlled substances
  • Government studies and investigations
  • International law and treaties
  • Licensing and registrations
  • Manufacturing
  • Research administration and funding
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.